Ascendis Pharma A/S

ASNDNASDAQ · USD
275.39USD0.00 (+3.12%)
642

Ascendis Pharma A/S (ASND) Historical Volatility

ASND's 30 day historical volatility is 24.45%, in the 3rd percentile of readings over the past year. This is a low percentile, meaning Ascendis Pharma A/S shares have been calmer than usual. ASND's 30 day implied volatility sits at 34.23%, with an IV Rank of 1.59%, leaving IV 9.78 points above historical volatility. This means options are pricing in more movement than the stock has actually delivered, as of Nov 13, 2026.

Read more

Tracking ASND historical volatility helps you see how much Ascendis Pharma A/S's stock price has actually moved, giving you a baseline for whether option premiums look fair, cheap, or expensive. While implied volatility shows what the market expects, ASND's HV, also known as realized volatility, shows what actually happened. Use our scanner to monitor ASND 30 day historical volatility alongside longer lookback windows and spot the moments when realized and implied diverge.

Historical volatility is the annualized standard deviation of a stock's past returns, typically measured over rolling windows like 10, 20, 30, or 60 days. ASND's 30 day historical volatility, or ASND HV, is one of the most widely watched readings because it balances responsiveness with stability. Comparing ASND's HV to its implied volatility reveals the volatility risk premium. When IV sits well above HV, options are pricing in more movement than the stock has actually delivered, giving option sellers an edge. When HV runs hot relative to IV, options are pricing in less movement than the stock has delivered, and buyers may be underpaying for it.

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/g for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

Historical Volatility

HV Percentile
3rdHV Percentile
Low

Historical movement is subdued versus the past year. The stock has been unusually quiet.

Historical Volatility (30d)24.45%

HV Percentile3rd

Implied Volatility (30d)34.23%

IV Rank1.59%

IV Minus HV+9.78%

As of Nov 13, 2026

IV vs HV
Implied Volatility (IV) vs Historical Volatility (HV) over the past month.

As of Nov 13, 2026

IV - HV Difference
Difference between IV and HV over time. Positive values indicate IV > HV.

As of Nov 13, 2026

Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →